Study on Savolitinib Combined With Osimertinib in Treatment of Advanced NSCLC With MET Amplification
Status:
Not yet recruiting
Trial end date:
2024-11-30
Target enrollment:
Participant gender:
Summary
This study will look at how effective the study drug(Savolitinib combined with Osimertinib)
versus Pemetrexed combined with platinum in treatment of patients with locally advanced or
metastatic NSCLC with MET amplification after failure of the first-line EGFR inhibitor
therapy.